Venizelos I, Tamiolakis D, Bolioti S, Nikolaidou S
Department of Pathology, Ippokration Hospital of Salonica, Greece.
Rev Esp Enferm Dig. 2007 May;99(5):270-4. doi: 10.4321/s1130-01082007000500005.
It is doubtful that whoever is suffering from gastric malt lymphoma will escape from the disease, if treated with medication against helicobacter pylori.
A cohort of 18 patients was analysed. Ten hosts had primary gastric malt lymphoma and were treated with gastric resection as the initial therapy. Eight hosts received antibiotics against Helicobacter pylori as the initial treatment. In all 18 patients Helicobacter pylori status, endoscopic findings and pathology features were evaluated. Immunohistochemistry was performed to assess the bcl-2 and p53 status.
Patients with low grade malt lymphoma: a) were Helicobacter pylori positive (5 of 5); b) had a superficial lesion (5 of 5); c) had no lymph node involvement (5 of 5); and d) were downstaged by comparison to patients with high grade tumor. Bcl-2 was positive in 4 of 5 low grade tumors, and p53 was positive in 12 of 13 high grade ones. Investigation of patients with 5-year follow up (n = 18) revealed that all but one low-grade tumors remained superficial with no progression. These tumors were bcl-2+/p53-, and the one with a bcl-2+/p53+ immunophenotype progressed to an ulcerated low-grade tumor after disappearance of Helicobacter pylori. Complete regression was found in 6 of 8 patients from the non surgically treated group (n = 8) after Helicobacter pylori eradication. These tumors were superficial/low grade/node negative/bcl-2+/p53 inconclusive (n = 2), superficial/low grade/node negative/bcl-2+/p53- (n = 2), and ulcerative/high grade/node negative/bcl-2+/p53- (n = 2). The two persistent tumors were ulcerative/high grade/node negative/bcl-2+/p53+.
Gastric malt lymphoma Helicobacter pylori+/superficial/low grade/bcl-2+/p53- will disappear after Helicobacter pylori eradication.
对于患有胃黏膜相关淋巴组织淋巴瘤的患者,若采用抗幽门螺杆菌药物治疗,是否能治愈该病仍存疑问。
分析了一组18例患者。10例患者患有原发性胃黏膜相关淋巴组织淋巴瘤,初始治疗采用胃切除术。8例患者初始治疗采用抗幽门螺杆菌抗生素。对所有18例患者的幽门螺杆菌感染状况、内镜检查结果及病理特征进行了评估。采用免疫组织化学方法评估bcl-2和p53的状态。
低度胃黏膜相关淋巴组织淋巴瘤患者:a)幽门螺杆菌检测呈阳性(5例中的5例);b)有浅表病变(5例中的5例);c)无淋巴结受累(5例中的5例);d)与高度肿瘤患者相比,分期降低。5例低度肿瘤中有4例bcl-2呈阳性,13例高度肿瘤中有12例p53呈阳性。对18例患者进行5年随访调查发现,除1例低度肿瘤外,其余所有低度肿瘤均保持浅表状态,无进展。这些肿瘤为bcl-2+/p53-,1例具有bcl-2+/p53+免疫表型的肿瘤在幽门螺杆菌消失后进展为溃疡性低度肿瘤。在未接受手术治疗的8例患者(n = 8)中,6例在根除幽门螺杆菌后完全缓解。这些肿瘤为浅表/低度/无淋巴结转移/bcl-2+/p53结果不确定(n = 2)、浅表/低度/无淋巴结转移/bcl-2+/p53-(n = 2)以及溃疡性/高度/无淋巴结转移/bcl-2+/p53-(n = 2)。2例持续存在的肿瘤为溃疡性/高度/无淋巴结转移/bcl-2+/p53+。
根除幽门螺杆菌后,幽门螺杆菌阳性/浅表/低度/bcl-2+/p53-的胃黏膜相关淋巴组织淋巴瘤将会消失。